Conway Brian
Podsumowanie dorobku w bazie danych
3
publikacji (2017–2019)
8,395
łączny Impact Factor
200
łącznie punktów MNiSW
Identyfikatory
PBN
Profil w PBN BPP ID
41231Publikacje w latach
20
Punkty MNiSW w latach
200,000
Impact Factor w latach
8,3950
Statystyki wg charakteru
| Charakter formalny | Liczba prac |
|---|---|
| 2 | |
| 1 | |
| Razem | 3 |
Wyszukaj publikacje autora
Bez zaznaczonych filtrów wyszukiwanie pokaże wszystkie prace autora. Zaznacz typy, lata lub jednostki, żeby zawęzić wyniki.
Eksport publikacji
Najlepsze prace (punkty MNiSW)
- Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: an integrated analysis of 7 phase III studies. [AUT. KORESP.] GRAHAM R. FOSTER, [AUT.] GREGORY J. DORE, STANLEY WANG, JASON GREBELY, KENNETH E. SHERMAN, AXEL BAUMGARTEN, BRIAN CONWAY, DANIEL JACKSON, TARIK ASSELAH, MICHAEL GSCHWANTLER, KRZYSZTOF TOMASIEWICZ, HUMBERTO AGUILAR, ARMEN ASATRYAN, YIRAN HU, FEDERICO J. MENSA. Drug Alcohol Depend. 2019 vol. 194 s. 487-494, bibliogr. poz. 44. DOI: 10.1016/j.drugalcdep.2018.11.007
- Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. [AUT. KORESP.] JASON GREBELY, [AUT.] GREGORY J. DORE, NEGAR N. ALAMI, BRIAN CONWAY, JOHN F. DILLON, MICHAEL GSCHWANTLER, FRANCO FELIZARTA, CHRISTOPHE HÉZODE, KRZYSZTOF TOMASIEWICZ, LINDA M. FREDRICK, EMILY O. DUMAS, FEDERICO J. MENSA. Int. J. Drug Policy 2019 vol. 66 s. 73-79, bibliogr. poz. 39. DOI: 10.1016/j.drugpo.2019.01.011
Najlepsze prace (Impact Factor)
- Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. [AUT. KORESP.] JASON GREBELY, [AUT.] GREGORY J. DORE, NEGAR N. ALAMI, BRIAN CONWAY, JOHN F. DILLON, MICHAEL GSCHWANTLER, FRANCO FELIZARTA, CHRISTOPHE HÉZODE, KRZYSZTOF TOMASIEWICZ, LINDA M. FREDRICK, EMILY O. DUMAS, FEDERICO J. MENSA. Int. J. Drug Policy 2019 vol. 66 s. 73-79, bibliogr. poz. 39. DOI: 10.1016/j.drugpo.2019.01.011
- Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: an integrated analysis of 7 phase III studies. [AUT. KORESP.] GRAHAM R. FOSTER, [AUT.] GREGORY J. DORE, STANLEY WANG, JASON GREBELY, KENNETH E. SHERMAN, AXEL BAUMGARTEN, BRIAN CONWAY, DANIEL JACKSON, TARIK ASSELAH, MICHAEL GSCHWANTLER, KRZYSZTOF TOMASIEWICZ, HUMBERTO AGUILAR, ARMEN ASATRYAN, YIRAN HU, FEDERICO J. MENSA. Drug Alcohol Depend. 2019 vol. 194 s. 487-494, bibliogr. poz. 44. DOI: 10.1016/j.drugalcdep.2018.11.007
Najnowsze artykuły
- Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: an integrated analysis of 7 phase III studies. [AUT. KORESP.] GRAHAM R. FOSTER, [AUT.] GREGORY J. DORE, STANLEY WANG, JASON GREBELY, KENNETH E. SHERMAN, AXEL BAUMGARTEN, BRIAN CONWAY, DANIEL JACKSON, TARIK ASSELAH, MICHAEL GSCHWANTLER, KRZYSZTOF TOMASIEWICZ, HUMBERTO AGUILAR, ARMEN ASATRYAN, YIRAN HU, FEDERICO J. MENSA. Drug Alcohol Depend. 2019 vol. 194 s. 487-494, bibliogr. poz. 44. DOI: 10.1016/j.drugalcdep.2018.11.007
- Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. [AUT. KORESP.] JASON GREBELY, [AUT.] GREGORY J. DORE, NEGAR N. ALAMI, BRIAN CONWAY, JOHN F. DILLON, MICHAEL GSCHWANTLER, FRANCO FELIZARTA, CHRISTOPHE HÉZODE, KRZYSZTOF TOMASIEWICZ, LINDA M. FREDRICK, EMILY O. DUMAS, FEDERICO J. MENSA. Int. J. Drug Policy 2019 vol. 66 s. 73-79, bibliogr. poz. 39. DOI: 10.1016/j.drugpo.2019.01.011
Ostatnio edytowane
- Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: an integrated analysis of 7 phase III studies. [AUT. KORESP.] GRAHAM R. FOSTER, [AUT.] GREGORY J. DORE, STANLEY WANG, JASON GREBELY, KENNETH E. SHERMAN, AXEL BAUMGARTEN, BRIAN CONWAY, DANIEL JACKSON, TARIK ASSELAH, MICHAEL GSCHWANTLER, KRZYSZTOF TOMASIEWICZ, HUMBERTO AGUILAR, ARMEN ASATRYAN, YIRAN HU, FEDERICO J. MENSA. Drug Alcohol Depend. 2019 vol. 194 s. 487-494, bibliogr. poz. 44. DOI: 10.1016/j.drugalcdep.2018.11.007
- Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. [AUT. KORESP.] JASON GREBELY, [AUT.] GREGORY J. DORE, NEGAR N. ALAMI, BRIAN CONWAY, JOHN F. DILLON, MICHAEL GSCHWANTLER, FRANCO FELIZARTA, CHRISTOPHE HÉZODE, KRZYSZTOF TOMASIEWICZ, LINDA M. FREDRICK, EMILY O. DUMAS, FEDERICO J. MENSA. Int. J. Drug Policy 2019 vol. 66 s. 73-79, bibliogr. poz. 39. DOI: 10.1016/j.drugpo.2019.01.011
- Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 and recent drug use. [AUT.] GRAHAM R. FOSTER, JASON GREBELY, KENNETH E. SHERMAN, STANLEY WANG, GREGORY J. DORE, AXEL BAUMGARTEN, BRIAN CONWAY, DANIEL F. JACKSON, TARIK ASSELAH, MICHAEL GSCHWANTLER, KRZYSZTOF TOMASIEWICZ, HUMBERTO I. AGUILAR, NEGAR NIKI ALAMI, EMILY O. DUMAS, YIRAN HU, FEDERICO J. MENSA. Hepatology 2017 vol. 66 suppl. 1 s. 636A-637A, The 68th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting. Washington, October 20-24, 2017. Abstr.
Osadź publikacje tego autora na swojej stronie WWW — kliknij tutaj.